Detail Natural Justice; Biotechnology Patents   Oleh:  [s.n] Jenis: Article from Bulletin/Magazine Dalam koleksi: The Economist (http://search.proquest.com/) vol. 407 no. 8832 (Apr. 2013), page 75. Topik: Supreme Court Decisions; Genomics; Patent Law Ketersediaan Perpustakaan Pusat (Semanggi) Nomor Panggil: EE29.76 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada     Lihat Detail Induk Isi artikel The nine justices on America's Supreme Court must apply their minds to the thorniest of legal questions. On April 15th they were presented with a particularly testing puzzler: should the law allow people to patent human genes? The case is the culmination of a battle that began in 2009. It pits America's Association for Molecular Pathology and various other interested parties--represented by lawyers from the American Civil Liberties Union--against Myriad Genetics, a biotechnology firm that holds patents on two human genes, called BRCA1 and BRCA2. That makes Myriad the sole producer of tests to detect mutations in those genes. Such mutations often increase a woman's risk of developing breast or ovarian cancer. It is an emotionally charged question. Patent offices around the world have been granting patents on genes, human and otherwise, for decades, but time has done little to soften opposition to the idea. Laymen are often baffled when they find out that it is possible to patent parts of the human genome. Anti-patenting campaigners argue that the idea of claiming a patent over the shared genetic heritage of the human race is absurd, immoral or both. Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved